How the GERD Diagnosis and Reflux Testing Actually Work

Heartburn is one of the most common reasons people ask for a diagnosis, yet the American College of Gastroenterology's 2022 guideline confirms gastroesophageal reflux disease (GERD) in an order that surprises most patients: treatment first, tests later. For someone with classic heartburn and regurgitation and no warning signs, the recommended opening move is an eight-week trial of a once-daily proton pump inhibitor (PPI) taken before a meal, not a camera or a probe. The scope and the pH study exist for the cases that break the pattern, and one of their most useful jobs is telling you when the problem was never acid at all.

Key points#

• The guideline starts classic, low-risk heartburn on an eight-week PPI trial because it treats the likely cause and gathers information at once.
• Symptom relief on a PPI is supportive, not proof: pooled sensitivity is roughly 78% and specificity only about 54%.
• Warning signs (trouble or pain swallowing, weight loss, bleeding, anemia, a mass) move upper endoscopy to the front.
• Ambulatory pH or impedance monitoring is the only test that measures acid directly, and it is run off therapy to diagnose and on therapy to explain persistent symptoms.
• Normal acid contact with ongoing symptoms points to reflux hypersensitivity or functional heartburn, which do not respond to more acid suppression.

Why the first step is a treatment, not a test#

GERD is common, and the pairing of heartburn with regurgitation in a person who has no alarm features is distinctive enough that starting therapy is both reasonable and economical. So the guideline recommends the eight-week PPI course as step one for exactly this group and holds objective testing for later.

Calling this a trial rather than a diagnostic test is a matter of honesty about the numbers. When PPI response is measured against the reference standards of endoscopy and pH monitoring, pooled sensitivity lands near 78% and specificity only around 54%. Put plainly, a PPI can relieve symptoms that acid never caused, and it can fail against symptoms that acid did cause. That is why improvement counts as supporting evidence rather than confirmation, and why the guideline discourages chasing a partial response with steadily larger doses. In one frequently cited multicenter study, only about 21% of patients whose heartburn persisted on a PPI turned out to have genuinely treatment-resistant GERD. The majority had a different problem wearing the same symptom.

When the camera goes first: the warning signs#

A specific set of features overrides the treat-first default and sends a patient to upper endoscopy right away. Difficulty swallowing, painful swallowing, unintentional weight loss, gastrointestinal bleeding or iron-deficiency anemia, and a palpable mass each warrant a scope, because any of them can flag a stricture, a cancer, or another structural cause that acid suppression would only paper over. Endoscopy is also appropriate for people carrying several risk factors for Barrett's esophagus, the precancerous lining change that long-standing reflux can drive.

Timing is the part clinicians most often get wrong. The guideline advises scoping after PPIs have been stopped for two weeks, and up to four when it is feasible, so that erosive esophagitis has not healed out of sight and so that eosinophilic esophagitis, an allergic condition that convincingly imitates reflux, is not overlooked. A scope that shows erosive disease or Barrett's confirms GERD on the spot. A normal scope, which is the more common outcome, clears the dangerous look-alikes but does not by itself rule reflux in or out.

Measuring the acid directly#

Ambulatory reflux monitoring is the only test that actually counts acid in the esophagus, and the guideline reserves it for defined situations: when the diagnosis stays unproven after an inconclusive trial, when symptoms continue despite treatment, and before any antireflux surgery or endoscopic procedure. How the study is set up depends on the question being asked.

If GERD has never been established objectively, the study is run off PPI therapy to find out whether abnormal reflux exists in the first place. If GERD is already documented and the real question is why symptoms persist, the study is run on therapy, usually with impedance added, so it can capture the weakly acidic and nonacid reflux that a pH sensor alone would miss. A wireless capsule pinned to the esophageal lining records for 48 to 96 hours and tends to be more comfortable, while a slim transnasal catheter is the tool of choice when impedance is needed.

The thresholds that settle these studies come from the Lyon Consensus, the international framework the field now leans on. Acid contact time, the share of the day the esophageal lining sits below pH 4, carries most of the interpretation: above 6% is conclusive for abnormal reflux, below 4% is normal, and the 4% to 6% band is borderline and needs corroboration. In that middle zone the guideline turns to adjunctive metrics, since a low mean nocturnal baseline impedance leans toward reflux disease, while a tight link between reflux episodes and the patient's own symptoms raises confidence that the two are genuinely connected.

When the test rewrites the diagnosis#

This is where monitoring pays for itself. When acid contact is normal but reflux events still track closely with symptoms, the label shifts to reflux hypersensitivity. When acid contact is normal and there is no symptom association, the diagnosis becomes functional heartburn, a disorder of how the esophagus processes pain rather than a problem of acid. Neither improves with more acid suppression, and naming them steers care toward the treatments that actually work, such as neuromodulators and brain-gut behavioral therapies.

High-resolution manometry has a supporting role here. It is not a test for GERD, but the guideline recommends it before antireflux surgery, partly to exclude achalasia, a motility disorder that can pose as reflux and that a fundoplication would make worse. The overall sequence, empiric therapy, then endoscopy when it is warranted, then physiologic testing before anything irreversible, is built to keep people from being handed a surgery for a disease they do not have.

What this means when reflux will not quit#

The practical lesson is that symptoms persisting on a PPI are a reason to test, not an automatic reason to push the dose higher. Objective measurement can confirm reflux, reclassify it, or send the search in a new direction, and each of those answers changes the next step. If your heartburn is not settling, the more useful conversation with your clinician is often about testing, not about a bigger prescription.